Adaptive Biotech product 'clonoSEQ' is the first MRD test cleared by FDA for multiple myeloma, CLL, and B-ALL. See why investors should consider adding ADPT stock to their portfolio.
/PRNewswire/ The National Comprehensive Cancer Center (NCCN®) a nonprofit alliance of leading cancer centers announces updates to its widely-used resource.